Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

This study is comparing two treatment approaches for men with newly diagnosed metastatic hormone-sensitive prostate cancer (prostate cancer that has spread but still responds to hormone therapy): rezvilutamide (a newer androgen blocker) plus hormone therapy alone versus rezvilutamide plus hormone therapy plus docetaxel chemotherapy. **You may be eligible if:** - You are a man aged 40–80 with confirmed prostate cancer that has spread to other parts of the body - Your cancer is high-burden (4 or more bone metastases, or spread to organs) - You are eligible for hormone therapy and chemotherapy - Your hormone therapy was started no more than 12 weeks ago - Your blood counts and organ function meet minimum requirements **You may NOT be eligible if:** - You have previously received advanced hormone blockers (e.g., enzalutamide, abiraterone, darolutamide) - You have had prior treatment with docetaxel for metastatic prostate cancer - You have uncontrolled heart disease, severe liver problems, or active serious infections Talk to your doctor to see if this trial is right for you.